Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

ACCREDITED SYMPOSIA

204 - Lp(a): A SMALL PARTICLE WITH A LARGE IMPACT – 10 THINGS YOU NEED TO KNOW ABOUT THIS HIDDEN, INHERITED, INDEPENDENT RISK FACTOR

Friday, October 25, 2024
12:30 PM – 1:30 PM PT
Room: 118-120
On-Demand
Lipoprotein(a) [Lp(a)] is an inherited, independent risk factor that promotes the development and progression of cardiovascular disease through multiple pathways. It is often referred to as a “hidden” risk because most patients have never had their Lp(a) levels tested. The 2021 Canadian Cardiovascular Society (CCS) Dyslipidemia Guidelines recommended measuring Lp(a) levels at least once in a person’s lifetime, leading to an increase in testing rates in recent years. Join us for this highly interactive symposium designed to enhance your understanding of Lp(a). Through key facts, expert panel discussions, and case-based scenarios, you will have the opportunity to test your knowledge and explore critical questions on topics such as the pathophysiology of Lp(a), the benefits of Lp(a) testing for comprehensive cardiovascular risk stratification, and evidence-based risk management strategies for your patients with elevated Lp(a).

Learning Objectives:

At the end of this session participants will be able to:
  • describe how Lp(a) promotes the development and progression of cardiovascular diseases independently of traditional cardiovascular risk factors (Medical Expert, Scholar)
  • identify which patients would benefit the most from testing, how to communicate test results with patients, and the benefits of cascade testing (Health Advocate, Communicator)
  • interpret Lp(a) test results to inform and personalize CV risk management strategies for patients with elevated levels (Medical Expert, Health Advocate)
Disclosure(s):
Liam R. Brunham, MD PhD FRCPC: Amgen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Ultragenyx: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)
Sonia S. Anand, MD, PhD, FRCPC: Bayer AG: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Daiichi Sankyo: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Janssen Pharmaceuticals: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); novartis: speaker (Ongoing); Novonordisk: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)